126 related articles for article (PubMed ID: 32197755)
1. Impact of liraglutide on microcirculation in experimental diabetic cardiomyopathy.
Abdelrazik Soliman NG; Abdel-Hamid AAM; El-Hawwary AA; Ellakkany A
Acta Histochem; 2020 Apr; 122(3):151533. PubMed ID: 32197755
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
[TBL] [Abstract][Full Text] [Related]
3. Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats.
Cai H; Zhou L; Liu J; Li Z; Chen S
Biochem Biophys Res Commun; 2022 Nov; 629():112-120. PubMed ID: 36116373
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats.
Inoue T; Inoguchi T; Sonoda N; Hendarto H; Makimura H; Sasaki S; Yokomizo H; Fujimura Y; Miura D; Takayanagi R
Atherosclerosis; 2015 May; 240(1):250-9. PubMed ID: 25818251
[TBL] [Abstract][Full Text] [Related]
5. Favorable outcomes of metformin on coronary microvasculature in experimental diabetic cardiomyopathy.
Abdel-Hamid AAM; Firgany AEL
J Mol Histol; 2018 Dec; 49(6):639-649. PubMed ID: 30317407
[TBL] [Abstract][Full Text] [Related]
6. Effect of liraglutide on microcirculation in rat model with absolute insulin deficiency.
Ivanov AN; Lagutina DD; Saveleva MS; Popyhova EB; Stepanova TV; Savkina AA; Pylaev TE; Kuznetsova NA
Microvasc Res; 2021 Nov; 138():104206. PubMed ID: 34119534
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide alleviates cardiac fibrosis through inhibiting P4hα-1 expression in STZ-induced diabetic cardiomyopathy.
Zhao T; Chen H; Xu F; Wang J; Liu Y; Xing X; Guo L; Zhang M; Lu Q
Acta Biochim Biophys Sin (Shanghai); 2019 Mar; 51(3):293-300. PubMed ID: 30883649
[TBL] [Abstract][Full Text] [Related]
8. Diazoxide preconditioning of endothelial progenitor cells from streptozotocin-induced type 1 diabetic rats improves their ability to repair diabetic cardiomyopathy.
Ali M; Mehmood A; Anjum MS; Tarrar MN; Khan SN; Riazuddin S
Mol Cell Biochem; 2015 Dec; 410(1-2):267-79. PubMed ID: 26359087
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of diabetic cardiomyopathy by relying on kirenol to suppress inflammation in a diabetic rat model.
Wu B; Huang XY; Li L; Fan XH; Li PC; Huang CQ; Xiao J; Gui R; Wang S
J Cell Mol Med; 2019 Nov; 23(11):7651-7663. PubMed ID: 31565849
[TBL] [Abstract][Full Text] [Related]
10. The Potential Role of Undercarboxylated Osteocalcin Upregulation in Microvascular Insufficiency in a Rat Model of Diabetic Cardiomyopathy.
Sadek NB; Gamal SM; Aboulhoda BE; Rashed LA; Shawky HM; Gamal El-Din MM
J Cardiovasc Pharmacol Ther; 2020 Jan; 25(1):86-97. PubMed ID: 31533469
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide alleviates diabetic cardiomyopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-α pathway.
Ji Y; Zhao Z; Cai T; Yang P; Cheng M
Mol Med Rep; 2014 Apr; 9(4):1254-8. PubMed ID: 24535553
[TBL] [Abstract][Full Text] [Related]
12. Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis.
El-Shafey M; El-Agawy MSE; Eldosoky M; Ebrahim HA; Elsherbini DMA; El-Sherbiny M; Asseri SM; Elsherbiny NM
Front Endocrinol (Lausanne); 2022; 13():862394. PubMed ID: 35370937
[TBL] [Abstract][Full Text] [Related]
13. Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat.
Tate M; Deo M; Cao AH; Hood SG; Huynh K; Kiriazis H; Du XJ; Julius TL; Figtree GA; Dusting GJ; Kaye DM; Ritchie RH
Diab Vasc Dis Res; 2017 Sep; 14(5):423-433. PubMed ID: 28565941
[TBL] [Abstract][Full Text] [Related]
14. Liraglutide Effect on Ventricular Transient Outward K + Channel and Connexin-43 Protein Expression.
Ramadan NM; Malek HA; Rahman KA; El-Kholy E; Shaalan D; Elkashef W
Exp Clin Endocrinol Diabetes; 2021 Dec; 129(12):899-907. PubMed ID: 32559789
[TBL] [Abstract][Full Text] [Related]
15. Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway.
Wang L; Li J; Li D
Int J Clin Exp Pathol; 2015; 8(1):466-73. PubMed ID: 25755735
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin-induced diabetic rats.
Baylan U; Korn A; Emmens RW; Schalkwijk CG; Niessen HWM; Krijnen PAJ; Simsek S
Eur J Clin Invest; 2022 Sep; 52(9):e13807. PubMed ID: 35488737
[TBL] [Abstract][Full Text] [Related]
17. Neuregulin-1 Promotes Myocardial Angiogenesis in the Rat Model of Diabetic Cardiomyopathy.
Gui C; Zeng ZY; Chen Q; Luo YW; Li L; Chen LL
Cell Physiol Biochem; 2018; 46(6):2325-2334. PubMed ID: 29742506
[TBL] [Abstract][Full Text] [Related]
18. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor.
Yoon YS; Uchida S; Masuo O; Cejna M; Park JS; Gwon HC; Kirchmair R; Bahlman F; Walter D; Curry C; Hanley A; Isner JM; Losordo DW
Circulation; 2005 Apr; 111(16):2073-85. PubMed ID: 15851615
[TBL] [Abstract][Full Text] [Related]
19. Impact of vildagliptin on vascular and fibrotic remodeling of myocardium in experimental diabetic cardiomyopathy.
Abdel-Hamid AAM; Firgany AEL
Acta Histochem; 2020 Feb; 122(2):151499. PubMed ID: 31889531
[TBL] [Abstract][Full Text] [Related]
20. Argatroban Attenuates Diabetic Cardiomyopathy in Rats by Reducing Fibrosis, Inflammation, Apoptosis, and Protease-Activated Receptor Expression.
Bulani Y; Sharma SS
Cardiovasc Drugs Ther; 2017 Jun; 31(3):255-267. PubMed ID: 28695302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
